Market news

Delaware judge lets Monsanto’s mRNA patent lawsuits vs Pfizer, BioNTech, and Moderna proceed. Read more here.

BioNTech (BNTX) is closing three German sites it failed to sell in a shift away from pandemic-era ma

Detailed price information for Netflix Inc (NFLX-Q) from The Globe and Mail including charting and trades.

Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase.

BioNTech (NASDAQ:BNTX) said on Monday that it will close manufacturing facilities in Germany and Singapore after a sales process for the sites did not result in completed transactions. The German vaccine maker had announced in May that it would seek buyers for facilities in Idar-Oberstein, Marburg and Tuebingen in Germany, as well as its Singapore site, with closures planned if purchasers could not be found.

Pharmaceutical giant BioNTech, known worldwide for its development of a coronavirus vaccine, is set to close three plants in Germany, affecting 1,800 jobs. The Mainz-based company said on Monday that it will shutter the three sites in Idar-Oberstein, Marburg and Tübingen after no buyer could be found to take them on.

In mid-September 2026, Pfizer Canada and BioNTech announced Health Canada’s approval of the Omicron XFG‑adapted COMIRNATY vaccine for individuals aged 6 months and older, aligning with 2026–2027 public health recommendations. A few days earlier, BioNTech and OncoC4 reported that investigational CTLA‑4 antibody gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial stage, underscoring BioNTech’s expanding presence in late‑stage oncology. We’ll...

The company is looking to prove it can achieve significant success outside the coronavirus market.

Investors buying this biotech stock now will get its pipeline essentially for free.

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual Phase 3 melanoma data remains unseen. Here is why the scheduling alone is moving markets and what it signals about what that dataset might show.

Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.

BioNTech has been in focus again after fresh clinical trial results, yet the long slide in the share price keeps pulling attention back to a simple question about what investors are paying for its sales. With the stock well below where it traded several years ago, the issue is whether today’s valuation rests on a solid revenue base or on expectations that are hard to pin down. Over the past 5 years the share price has fallen 71.5%, which puts the spotlight firmly on whether the current...

BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy. At around US$96.69 per share, BioNTech has seen a 30 day share price return of 3.87% and a 90 day share price return of 4.85%, while the 1 year total shareholder return declined 2.59% and the 5 year total shareholder return fell 71.40%. This suggests that...

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the […]

If a new drug's the survival benefit is confirmed in the next leg of a late-stage study, the drug could provide a chemotherapy-free option for some lung cancers.

On Monday, BioNTech SE (NASDAQ:BNTX) and OncoC4 Inc. released the first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial. The data indicate their investigational therapy nearly doubled survival times compared to standard chemotherapy for a specific patient population. Following the announcement, the stock jumped nearly 2%. Evaluating Gotistobart for Lung Cancer The study investigates gotistobart (BNT316 or ONC-392) for metastatic squamous non-small cell lun

Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains why.

BioNTech SE (NASDAQ:BNTX) shares fell 1. 2% to $102.

BioNTech SE (BNTX) has an average rating of overweight and mean price target of $119.05, according t

BioNTech SE (NASDAQ:BNTX) is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an independent monitoring committee concluded that continuing the trial was unlikely to demonstrate effectiveness. The decision is more concerning than a routine trial disappointment because the committee identified a numerical imbalance in overall survival between the study groups. […]

The company is coming back into the spotlight thanks to recent developments.

BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.

BioNTech (NasdaqGS:BNTX) halted a Phase 2 trial of its individualized mRNA immunotherapy in colorectal cancer after an independent Data Safety Monitoring Board recommended termination for futility. The board cited a numerical imbalance in overall survival between treatment arms as a key factor in its decision. The discontinued study involved BioNTech's collaboration with Genentech and targeted colorectal cancer, an area described as having significant unmet medical need. This is the first...

BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. Click for more on BNTX.

Arcturus (ARCT), Moderna (MRNA), and Merck (MRK) fall after a mid-stage trial setback for a cancer shot developed by BioNTech (BNTX) and Roche (RHHBY). Read more here.

BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical